Zhejiang Hisoar Pharmaceutical Hits Day High with 9.96% Surge

Zhejiang Hisoar Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 9.96% on February 26, 2026. The stock reached an intraday high of CNY 8.83, marking a notable achievement in a challenging market environment. Over the past week, the company has shown a robust performance with an 18.05% increase, significantly outpacing the China Shanghai Composite, which saw a modest gain of 0.41%. In the longer term, Zhejiang Hisoar has demonstrated impressive growth, with a 37.97% rise over the past month and an 84.73% increase over the past year, compared to the China Shanghai Composite's 22.49% return. Despite these positive short-term trends, the company faces underlying challenges, including a low Return on Capital Employed (ROCE) of 2.16% and a declining net sales growth rate of -6.39% over the last five years. The stock's performance remains a focal point in the pharmaceuticals and biotechnology sector, reflecting both its recent gains and the complexities of its financial health.